Mutations in CHEK2 Associated with Prostate Cancer Risk
AUTOR(ES)
Dong, Xiangyang
FONTE
The American Society of Human Genetics
RESUMO
The DNA-damage–signaling pathway has been implicated in all human cancers. However, the genetic defects and the mechanisms of this pathway in prostate carcinogenesis remain poorly understood. In this study, we analyzed CHEK2, the upstream regulator of p53 in the DNA-damage–signaling pathway, in several groups of patients with prostate cancer. A total of 28 (4.8%) germline CHEK2 mutations (16 of which were unique) were found among 578 patients. Additional screening for CHEK2 mutations in 149 families with familial prostate cancer revealed 11 mutations (5 unique) in nine families. These mutations included two frameshift and three missense mutations. Importantly, 16 of 18 unique CHEK2 mutations identified in both sporadic and familial cases were not detected among 423 unaffected men, suggesting a pathological effect of CHEK2 mutations in prostate cancer development. Analyses of the two frameshift mutations in Epstein Barr virus–transformed cell lines, using reverse-transcriptase polymerase chain reaction and western blot analysis, revealed abnormal splicing for one mutation and dramatic reduction of CHEK2 protein levels in both cases. Overall, our data suggest that mutations in CHEK2 may contribute to prostate cancer risk and that the DNA-damage–signaling pathway may play an important role in the development of prostate cancer.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=379222Documentos Relacionados
- Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil
- A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast Cancer
- Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband
- Single nucleotide polymorphisms in DKK3 gene are associated with prostate cancer risk and progression
- Caracterização de um grupo de pacientes em risco para câncer de mama e cólon hereditários quanto a prevalência da seleção 1100C no gene CHEK2